Saturday, March 17, 2018

From Kelly Butnor and colleagues: Malignant Mesothelioma in Individuals With Nonmesothelial Neoplasms

Kelly J. ButnorMDElizabeth N. PavliskoMDThomas A. SpornMDVictor L. RoggliMD
From the Department of Pathology and Laboratory Medicine, University of Vermont, Burlington (Dr Butnor); and the Department of Pathology, Duke University, Durham, North Carolina (Drs Pavlisko, Sporn, and Roggli).
Reprints: Kelly J. Butnor, MD, Department of Pathology, University of Vermont Medical Center, ACC Bldg, EP2-120, 111 Colchester Ave, Burlington, VT 05401 (email: ).
Context.— Malignant mesothelioma (MM) is a component of the BAP1 tumor predisposition syndrome. Other than in BAP1familial studies, nonmesothelial neoplasms in individuals with MM has not been comprehensively assessed.
Objective.— To assess the spectrum and prevalence of nonmesothelial neoplasms in individuals with MM.
Design.— Individuals with MM and second neoplasms were identified from a database of 3900 MM cases. The expected prevalence of each type of neoplasm was calculated and compared with the actual prevalence in the study population using available Surveillance, Epidemiology, and End Results data and other published data.
Results.— Two hundred seventy nonmesothelial neoplasms were identified in 241 individuals (6% of the study population) with MM. Prostate adenocarcinoma was most common. Non-Hodgkin lymphoma, Hodgkin lymphoma, lung carcinoma, urothelial carcinoma, breast carcinoma, chronic lymphocytic leukemia, clear cell renal cell carcinoma, head and neck squamous cell carcinoma, papillary renal cell carcinoma, multiple myeloma/plasmacytoma, meningioma, pleomorphic undifferentiated sarcoma, chronic myelogenous leukemia, ocular melanoma, hepatocellular carcinoma, liposarcoma, and Wilms tumor all were more prevalent than expected.
Conclusions.— Nonmesothelial neoplasms are uncommon in individuals with MM, but certain tumor types are increased in prevalence. In an unselected study population with respect to BAP1 status, the prevalence of several tumor types described in BAP1 mutation carriers, including lung carcinoma, clear cell renal cell carcinoma, breast carcinoma, meningioma, pleomorphic undifferentiated sarcoma, and ocular melanoma, was increased.

No comments:

Post a Comment